Abvc Biopharma (ABVC) EBITDA (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly EBITDA came in at -$1.6 million in Q1 2026, down 126.91% YoY from $5.8 million in Q1 2025, and up 28.49% on a QoQ basis from -$2.2 million in Q4 2025.
Abvc Biopharma (ABVC) EBITDA (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 16 years of EBITDA data on file, last reported at -$1.6 million in Q1 2026.
- Quarterly EBITDA fell 126.91% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.0 million (down 213.7% YoY) and the FY2025 annual result came in at -$7.2 million, down 51.98% from the prior year.
- EBITDA advanced to -$1.6 million in Q1 2026, from -$2.2 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$302316.0 in Q3 2024 to a low of -$6.2 million in Q1 2022.
- A 5-year average of -$2.1 million and a median of -$2.0 million in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2024 — EBITDA jumped 85.97% — and 2025, when it sank 549.77%.
- Tracing ABVC's EBITDA over 5 years: stood at -$3.1 million in 2022, then surged by 83.66% to -$511835.0 in 2023, then tumbled by 37.65% to -$704564.0 in 2024, then sank by 212.1% to -$2.2 million in 2025, then rose by 28.49% to -$1.6 million in 2026.
- The last three EBITDA figures came in at -$1.6 million (Q1 2026), -$2.2 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Abvc Biopharma | 23.34 Mn | 23.34 Mn | - | -779,526.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -779,526.00 |
| Mar 31, 2026 | -1.57 Mn |
| Dec 31, 2025 | -2.20 Mn |
| Sep 30, 2025 | -1.96 Mn |
| Jun 30, 2025 | -2.29 Mn |
| Mar 31, 2025 | -693,005.00 |
| Dec 31, 2024 | -704,564.00 |
| Sep 30, 2024 | -302,316.00 |
| Jun 30, 2024 | -860,107.00 |
| Mar 31, 2024 | -2.84 Mn |
| Dec 31, 2023 | -511,835.00 |
| Sep 30, 2023 | -2.15 Mn |
| Jun 30, 2023 | -2.19 Mn |
| Mar 31, 2023 | -1.91 Mn |
| Dec 31, 2022 | -3.13 Mn |
| Sep 30, 2022 | -3.72 Mn |
| Jun 30, 2022 | -2.05 Mn |
| Mar 31, 2022 | -6.22 Mn |
| Dec 31, 2021 | -6.45 Mn |
| Sep 30, 2021 | -1.97 Mn |